361 related articles for article (PubMed ID: 8607111)
1. A comparative study of the anticoagulant and anti-thrombotic effects of unfractionated heparin and a low molecular weight heparin (Fraxiparine) in an experimental model of human venous thrombosis.
Diquélou A; Dupouy D; Cariou R; Sakariassen KS; Boneu B; Cadroy Y
Thromb Haemost; 1995 Nov; 74(5):1286-92. PubMed ID: 8607111
[TBL] [Abstract][Full Text] [Related]
2. Comparison of a low-molecular-weight heparin (nadroparin calcium) and unfractionated heparin as adjunct to coronary thrombolysis with alteplase and aspirin in dogs.
Jun L; Arnout J; Vanhove P; Dol F; Lormeau JC; Herbert JM; Collen D; Van de Werf F
Coron Artery Dis; 1995 Mar; 6(3):257-63. PubMed ID: 7788040
[TBL] [Abstract][Full Text] [Related]
3. Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis.
Harenberg J; Stehle G; Blauth M; Huck K; Mall K; Heene DL
Semin Thromb Hemost; 1997; 23(1):83-90. PubMed ID: 9156415
[TBL] [Abstract][Full Text] [Related]
4. Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model.
Biemond BJ; Levi M; Nurmohamed MT; Büller HR; ten Cate JW
Thromb Haemost; 1994 Sep; 72(3):377-80. PubMed ID: 7855787
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics and tolerance of two nadroparin formulations (10,250 and 20,500 anti Xa IU x ml(-1)) delivered for 10 days at therapeutic dose.
Boneu B; Navarro C; Cambus JP; Caplain H; d'Azemar P; Necciari J; Duret JP; Gaud C; Sié P
Thromb Haemost; 1998 Feb; 79(2):338-41. PubMed ID: 9493587
[TBL] [Abstract][Full Text] [Related]
6. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin).
Mismetti P; Laporte-Simitsidis S; Navarro C; Sié P; d'Azemar P; Necciari J; Duret JP; Gaud C; Decousus H; Boneu B
Thromb Haemost; 1998 Jun; 79(6):1162-5. PubMed ID: 9657442
[TBL] [Abstract][Full Text] [Related]
7. Hemostatic activation under anticoagulant treatment: a comparison of unfractionated heparin vs. nadroparin in the treatment of proximal deep vein thrombosis.
Stricker H; Marchetti O; Haeberli A; Mombelli G
Thromb Haemost; 1999 Oct; 82(4):1227-31. PubMed ID: 10544903
[TBL] [Abstract][Full Text] [Related]
8. Anticoagulative effects of the inhaled low molecular weight heparin certoparin in healthy subjects.
Scheuch G; Brand P; Meyer T; Herpich C; Müllinger B; Brom J; Weidinger G; Kohlhäufl M; Häussinger K; Spannagl M; Schramm W; Siekmeier R
J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 2):603-14. PubMed ID: 18204174
[TBL] [Abstract][Full Text] [Related]
9. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome).
Eur Heart J; 1999 Nov; 20(21):1553-62. PubMed ID: 10529323
[TBL] [Abstract][Full Text] [Related]
10. A new method for quantifying platelet deposition in flowing native blood in an ex vivo model of human thrombogenesis.
Bossavy JP; Sakariassen KS; Barret A; Boneu B; Cadroy Y
Thromb Haemost; 1998 Jan; 79(1):162-8. PubMed ID: 9459343
[TBL] [Abstract][Full Text] [Related]
11. Relationship between endothelial tissue factor and thrombogenesis under blood flow conditions.
Diquélou A; Dupouy D; Gaspin D; Constans J; Sié P; Boneu B; Sakariassen KS; Cadroy Y
Thromb Haemost; 1995 Aug; 74(2):778-83. PubMed ID: 8585021
[TBL] [Abstract][Full Text] [Related]
12. Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers.
Azizi M; Veyssier-Belot C; Alhenc-Gelas M; Chatellier G; Billaud-Mesguish E; Fiessinger JN; Aiach M
Br J Clin Pharmacol; 1995 Dec; 40(6):577-84. PubMed ID: 8703665
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism).
Collignon F; Frydman A; Caplain H; Ozoux ML; Le Roux Y; Bouthier J; Thébault JJ
Thromb Haemost; 1995 Apr; 73(4):630-40. PubMed ID: 7495071
[TBL] [Abstract][Full Text] [Related]
14. Antifactor Xa activity in critically ill patients receiving antithrombotic prophylaxis with standard dosages of certoparin: a prospective, clinical study.
Jochberger S; Mayr V; Luckner G; Fries DR; Mayr AJ; Friesenecker BE; Lorenz I; Hasibeder WR; Ulmer H; Schobersberger W; Dünser MW
Crit Care; 2005 Oct; 9(5):R541-8. PubMed ID: 16277716
[TBL] [Abstract][Full Text] [Related]
15. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A
Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840
[TBL] [Abstract][Full Text] [Related]
16. alpha-thrombin bound to extracellular endothelial matrix induces pronounced fibrin deposition and platelet thrombus growth in flowing non-anticoagulated human blood.
Salatti JA; Fenton J; Anton P; Sakariassen KS
Blood Coagul Fibrinolysis; 1994 Aug; 5(4):561-6. PubMed ID: 7841312
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of platelet-dependent thrombosis by low molecular weight heparin (CY222): comparison with standard heparin.
Cadroy Y; Harker LA; Hanson SR
J Lab Clin Med; 1989 Oct; 114(4):349-57. PubMed ID: 2551985
[TBL] [Abstract][Full Text] [Related]
18. Recombinant full-length tissue factor pathway inhibitor (TFPI) prevents thrombus formation and rethrombosis after lysis in a rabbit model of jugular vein thrombosis.
Kaiser B; Fareed J
Thromb Haemost; 1996 Oct; 76(4):615-20. PubMed ID: 8903005
[TBL] [Abstract][Full Text] [Related]
19. Fibrinolytic and anticoagulant activity after a single subcutaneous administration of a low dose of heparin or a low molecular weight heparin-dihydroergotamine combination.
Grimaudo V; Omri A; Kruithof EK; Hauert J; Bachmann F
Thromb Haemost; 1988 Jun; 59(3):388-91. PubMed ID: 2847348
[TBL] [Abstract][Full Text] [Related]
20. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
Melo FR; Mourão PA
Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
